Sourcing Ionisable Lipids, PEG‑Lipids and Cholesterol for mRNA Lipid Nanoparticles

What should I consider when sourcing PEG‑lipids for mRNA LNPs?

PEG‑lipids provide steric stabilisation and control particle size. Their performance hinges on the PEG chain length, lipid anchor, and the mol% incorporated into the LNP.

• PEG molecular weight – 2 kDa PEG is common for LNPs, but 5 kDa can improve circulation time at the cost of reduced encapsulation efficiency. Verify the exact molecular weight by MALDI‑TOF or GPC.
• Lipid anchor – DSPE‑PEG, DMG‑PEG and cholesterol‑PEG are the main anchors. DSPE‑PEG offers a higher transition temperature, which can affect particle rigidity. Choose the anchor that matches your formulation’s fluidity requirements.
• End‑group functionality – Most PEG‑lipids are methoxy‑terminated (mPEG). For targeted delivery, consider functionalised end‑groups (e.g., NHS, maleimide) and ensure they are compatible with downstream conjugation chemistry.
• Regulatory status – PEG‑lipids used in clinical products must be listed in the USP <USP <>> or EP monographs and have a REACH registration. Some suppliers provide GMP‑grade PEG‑lipids with a full CoA and SDS.
• Batch consistency – Small variations in PEG chain length distribution can alter particle size by ±5 nm. Request batch‑to‑batch analytical data and, where possible, a certificate of analysis for each lot.

Find out more about Cholesterol on our product page →

A recent market analysis highlighted that several manufacturers are now offering PEG‑lipids with tighter dispersity (Đ < 1.05) to meet the stringent specifications of mRNA vaccines【. When sourcing, ask for the dispersity value and the method used to determine it (e.g., GPC).

Where to obtain cholesterol suitable for mRNA lipid nanoparticle formulation?

Cholesterol stabilises the lipid bilayer and modulates membrane fluidity. The quality of cholesterol can dramatically affect LNP integrity and mRNA release kinetics.

• Purity – Pharmaceutical‑grade cholesterol is typically ≥99 % pure, verified by HPLC and GC‑MS. Impurities such as oxysterols can promote oxidation of the LNP; therefore, request a CoA that includes an oxidation‑state analysis.
• Source – Cholesterol can be derived from animal (bovine) or plant (vegetable) origins. For regulatory compliance, especially in EU markets, plant‑derived cholesterol is often preferred to avoid animal‑derived contaminants.
• Stability additives – Some suppliers provide cholesterol pre‑mixed with antioxidants (e.g., BHT) to improve shelf‑life. Confirm that any additive is compatible with your mRNA and does not interfere with downstream assays such as HPLC or LC‑MS.
• Regulatory documentation – Ensure the cholesterol is listed in the USP <USP <>> or EP monographs and has a REACH registration. GMP‑certified cholesterol will be accompanied by an SDS, CoA and a batch‑specific certificate of compliance.

Industry news indicates a consolidation of cholesterol suppliers, with a few large manufacturers now offering bulk GMP‑grade cholesterol at reduced cost due to increased demand from mRNA vaccine production【. When negotiating price, consider long‑term supply agreements to lock in batch consistency.

What quality criteria apply to LNP components for mRNA therapeutics?

Across ionisable lipids, PEG‑lipids and cholesterol, the following quality criteria are universally applied:

| Criterion | Typical Requirement | |-----------|----------------------| | Purity | ≥99 % (HPLC/NMR) | | Residual solvents | ≤10 ppm (GC‑MS) | | Water content | ≤0.5 % (Karl Fischer) | | Heavy metals | ≤10 ppm (ICP‑MS) | | Endotoxin | ≤0.5 EU · mg⁻¹ (LAL) | | Documentation | SDS, CoA, REACH registration, GMP certificate |

Suppliers that provide full documentation and traceability simplify regulatory submissions for IND or CTA filings. Molekula maintains a curated portfolio of suppliers that meet these standards, offering a single point of contact for ordering and technical support.

Frequently asked

Q1: Can I use research‑grade ionisable lipids for pre‑clinical studies? A: Yes, provided the material has a documented purity ≥98 % and an accompanying CoA. However, for GLP or IND‑enabling work, GMP‑grade lipids are required.

Q2: How much PEG‑lipid should be included in an LNP formulation? A: Typical formulations use 1–2 mol % PEG‑lipid relative to total lipid. The exact amount depends on desired particle size and circulation time.

Q3: Is plant‑derived cholesterol interchangeable with bovine cholesterol? A: Chemically they are identical, but regulatory preferences and impurity profiles differ. Verify the source and impurity specifications before substitution.

Q4: What documentation is essential for regulatory filing? A: SDS, CoA, GMP certificate, REACH registration, and any relevant pharmacopeial monograph references (USP, EP, BP) are mandatory.